PL3024485T3 - Zastosowanie partnera wiążącego cd6 i oparty na tym sposób - Google Patents
Zastosowanie partnera wiążącego cd6 i oparty na tym sposóbInfo
- Publication number
- PL3024485T3 PL3024485T3 PL14828881T PL14828881T PL3024485T3 PL 3024485 T3 PL3024485 T3 PL 3024485T3 PL 14828881 T PL14828881 T PL 14828881T PL 14828881 T PL14828881 T PL 14828881T PL 3024485 T3 PL3024485 T3 PL 3024485T3
- Authority
- PL
- Poland
- Prior art keywords
- application
- binding partner
- partner
- binding
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Rehabilitation Therapy (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3264CH2013 | 2013-07-23 | ||
| EP14828881.4A EP3024485B1 (en) | 2013-07-23 | 2014-07-23 | Use of a cd6 binding partner and method based thereon |
| PCT/IB2014/063345 WO2015011658A1 (en) | 2013-07-23 | 2014-07-23 | Use of a cd6 binding partner and method based thereon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3024485T3 true PL3024485T3 (pl) | 2021-06-14 |
Family
ID=52392806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14828881T PL3024485T3 (pl) | 2013-07-23 | 2014-07-23 | Zastosowanie partnera wiążącego cd6 i oparty na tym sposób |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10189899B2 (pl) |
| EP (3) | EP3024485B1 (pl) |
| JP (4) | JP6530391B2 (pl) |
| KR (3) | KR102405247B1 (pl) |
| AR (1) | AR097038A1 (pl) |
| AU (3) | AU2014294616B2 (pl) |
| CA (1) | CA2920368C (pl) |
| DK (1) | DK3024485T3 (pl) |
| ES (1) | ES2843683T3 (pl) |
| HK (1) | HK1225298A1 (pl) |
| NZ (1) | NZ746944A (pl) |
| PL (1) | PL3024485T3 (pl) |
| PT (1) | PT3024485T (pl) |
| TW (1) | TW201511772A (pl) |
| WO (1) | WO2015011658A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113083A1 (en) | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
| EP3024485B1 (en) | 2013-07-23 | 2020-11-18 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
| JP7065085B2 (ja) * | 2016-10-18 | 2022-05-11 | バイオコン・リミテッド | Cd6のリン酸化を低減させるためのイトリズマブの使用 |
| ES2991182T3 (es) | 2016-10-21 | 2024-12-02 | Biocon Ltd | Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus |
| US12281151B2 (en) | 2018-06-29 | 2025-04-22 | City Of Hope | CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US20230364233A1 (en) * | 2020-09-28 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd6 modification |
| JP2023552762A (ja) * | 2020-12-04 | 2023-12-19 | エクイリウム,インコーポレイテッド | Cd6high細胞を選択的に標的化してteff細胞の活性を低下する方法 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US699755A (en) | 1902-03-06 | 1902-05-13 | Ira G Hoag | Train-order box in connection with semaphores. |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| EP0631783A1 (en) | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
| US5998172A (en) | 1993-11-02 | 1999-12-07 | Duke University | Anti-CD6 ligand antibodies |
| WO1995012614A1 (en) | 1993-11-02 | 1995-05-11 | Duke University | Cd6 ligand |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| AU5132096A (en) | 1995-01-30 | 1996-08-21 | Terrapin Technologies, Inc. | Glubodies - multiplicities of proteins capable of binding a variety of small molecules |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| CU22584A1 (es) | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| KR20000064710A (ko) | 1996-03-20 | 2000-11-06 | 제넨테크, 인코포레이티드 | 인테그린, 특히 ανβ3 인테그린에 대하여 특이 활성을갖는 3환식 화합물, 그 제조방법 및 그 제조를 위한 중간체, 의약으로서의 그 용도 및 그를 포함한 약제 조성물 |
| WO1998043089A1 (en) | 1997-03-03 | 1998-10-01 | Bristol-Myers Squibb Company | Monoclonal antibodies to human cd6 |
| WO1998047531A2 (en) | 1997-04-21 | 1998-10-29 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy |
| WO2000058362A1 (en) | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
| WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| WO2001070984A2 (en) | 2000-03-16 | 2001-09-27 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
| HK1054316A1 (zh) | 2000-05-26 | 2003-11-28 | Smithkline Beecham Corporation | 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体 |
| ES2192128B1 (es) | 2001-04-27 | 2005-01-01 | Universidad De Vigo | Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia. |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| US20040091490A1 (en) | 2002-08-28 | 2004-05-13 | Robert Johnson | Stable pH optimized formulation of a modified antibody |
| MXPA05010555A (es) | 2003-04-04 | 2006-03-09 | Genentech Inc | Formulaciones de proteina y anticuerpo de alta concentracion. |
| AU2005214382B2 (en) | 2004-02-19 | 2011-08-04 | Genentech, Inc. | CDR-repaired antibodies |
| CA2569509C (en) * | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| AU2005304624B2 (en) | 2004-11-12 | 2010-10-07 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PA8661401A1 (es) | 2005-01-28 | 2006-09-08 | Wyeth Corp | Formulaciones del liquido polipeptido estabilizado |
| WO2007142667A2 (en) | 2005-10-13 | 2007-12-13 | Human Genome Sciences, Inc. | Treatment of patients with autoantibody positive disease |
| CA2654794A1 (en) | 2006-06-14 | 2007-12-21 | Imclone Systems Incorporated | Lyophilized formulations of anti-egfr antibodies |
| CL2007003583A1 (es) | 2006-12-11 | 2008-07-18 | Hoffmann La Roche | Formulacion farmaceutica estable, parenteral, del anticuerpo contra el peptido beta amiloide (abeta); y uso de la formulacion para el tratamiento de la enfermedad de alzheimer. |
| CN101199483B (zh) | 2006-12-14 | 2011-01-26 | 上海中信国健药业股份有限公司 | 一种稳定的抗her2人源化抗体制剂 |
| KR101482959B1 (ko) | 2006-12-26 | 2015-01-15 | 센트로 데 인뮤놀러지아 모레큘러 | B-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물 |
| KR101482956B1 (ko) | 2006-12-26 | 2015-01-15 | 센트로 데 인뮤놀러지아 모레큘러 | 류마티스 관절염의 진단 및 치료에 사용되는 항-cd6 단일클론성 항체를 포함하는 약학 조성물 |
| CA2674608A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| JP2010111581A (ja) * | 2007-01-25 | 2010-05-20 | Imuno:Kk | ドーパミンd2様受容体アゴニストを有効成分とする医薬及びスクリーニング方法 |
| NZ579251A (en) * | 2007-02-28 | 2012-06-29 | Schering Corp | Engineered anti-il-23r antibodies |
| US20090208492A1 (en) | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| EP2170268A2 (en) | 2007-06-25 | 2010-04-07 | Amgen, Inc. | Compositions of specific binding agents to hepatocyte growth factor |
| WO2009037190A2 (en) | 2007-09-21 | 2009-03-26 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for il-ir antibody |
| WO2009092087A2 (en) * | 2008-01-18 | 2009-07-23 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
| WO2009113083A1 (en) | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
| EP2501408B1 (en) | 2009-11-20 | 2020-05-27 | Biocon Limited | Formulations of antibody |
| GB201013975D0 (en) * | 2010-08-20 | 2010-10-06 | Imp Innovations Ltd | Method of treating desease |
| US9216988B2 (en) * | 2011-12-22 | 2015-12-22 | Genentech, Inc. | Benzyl sulfonamide derivatives as RORc modulators |
| CN102559636B (zh) | 2011-12-30 | 2014-03-12 | 百泰生物药业有限公司 | 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法 |
| EP3024485B1 (en) | 2013-07-23 | 2020-11-18 | Biocon Limited | Use of a cd6 binding partner and method based thereon |
| JP7065085B2 (ja) | 2016-10-18 | 2022-05-11 | バイオコン・リミテッド | Cd6のリン酸化を低減させるためのイトリズマブの使用 |
| ES2991182T3 (es) | 2016-10-21 | 2024-12-02 | Biocon Ltd | Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus |
| CN112424226B (zh) | 2018-02-27 | 2025-03-14 | 平衡生物科技股份有限公司 | 用于治疗重度哮喘的抗cd6抗体 |
-
2014
- 2014-07-23 EP EP14828881.4A patent/EP3024485B1/en active Active
- 2014-07-23 EP EP20183825.7A patent/EP3738613A1/en not_active Withdrawn
- 2014-07-23 KR KR1020217020959A patent/KR102405247B1/ko active Active
- 2014-07-23 AU AU2014294616A patent/AU2014294616B2/en active Active
- 2014-07-23 EP EP21189911.7A patent/EP3936148A1/en active Pending
- 2014-07-23 CA CA2920368A patent/CA2920368C/en active Active
- 2014-07-23 HK HK16113658.8A patent/HK1225298A1/zh unknown
- 2014-07-23 US US14/905,506 patent/US10189899B2/en active Active
- 2014-07-23 NZ NZ746944A patent/NZ746944A/en unknown
- 2014-07-23 JP JP2016528639A patent/JP6530391B2/ja active Active
- 2014-07-23 ES ES14828881T patent/ES2843683T3/es active Active
- 2014-07-23 DK DK14828881.4T patent/DK3024485T3/da active
- 2014-07-23 KR KR1020167004764A patent/KR102034757B1/ko active Active
- 2014-07-23 KR KR1020197030291A patent/KR102276745B1/ko not_active Expired - Fee Related
- 2014-07-23 PL PL14828881T patent/PL3024485T3/pl unknown
- 2014-07-23 PT PT148288814T patent/PT3024485T/pt unknown
- 2014-07-23 WO PCT/IB2014/063345 patent/WO2015011658A1/en not_active Ceased
- 2014-07-24 TW TW103125275A patent/TW201511772A/zh unknown
- 2014-07-24 AR ARP140102744A patent/AR097038A1/es unknown
-
2018
- 2018-12-10 US US16/215,496 patent/US11028168B2/en active Active
-
2019
- 2019-03-15 JP JP2019047836A patent/JP6868655B2/ja not_active Expired - Fee Related
- 2019-10-08 AU AU2019246781A patent/AU2019246781B2/en active Active
-
2020
- 2020-12-03 JP JP2020200732A patent/JP7221264B2/ja active Active
-
2021
- 2021-05-04 US US17/307,351 patent/US20220025038A1/en not_active Abandoned
- 2021-10-01 AU AU2021240292A patent/AU2021240292B2/en not_active Expired - Fee Related
-
2022
- 2022-07-11 JP JP2022111409A patent/JP2022145689A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3052485T (pt) | Compostos heterocíclicos e suas utilizações | |
| HRP20181392T1 (hr) | Heterociklični spojevi i njihova uporaba | |
| DK3089994T3 (da) | Fabs-in-tandem-immunglobulin og anvendelser deraf | |
| LT3049441T (lt) | Anti-pdl1 antikūnų kompozicija | |
| DK3683235T3 (da) | Anti-IL-33-antistoffer og anvendelser deraf | |
| DK2968173T3 (da) | Heterocykliske forbindelser og anvendelser deraf | |
| EP2962216A4 (en) | COMMON USE OF APPLICATION STATES | |
| EP3039131C0 (en) | ENZYME COMPOSITION AND USES | |
| EP2987933A4 (en) | HINGE | |
| LT3038654T (lt) | Naujas panaudojimas | |
| DK3030549T3 (da) | Pyridazinonforbindelser og anvendelser deraf | |
| PL3024485T3 (pl) | Zastosowanie partnera wiążącego cd6 i oparty na tym sposób | |
| BR302013005487S1 (pt) | Configuração aplicada em aumotóvel | |
| DK2978414T3 (da) | Sammensætning omfattende hydrocortison | |
| BR302013005994S1 (pt) | Configuração aplicada em mixer | |
| FR3007291B1 (fr) | Composition cicatrisante et utlisation | |
| EP2985312A4 (en) | AGGREGATE AND COMPOSITION | |
| BR302013002605S1 (pt) | Configuração aplicada em banqueta | |
| BR302013005488S1 (pt) | Configuração aplicada em relógio | |
| BR302013005118S1 (pt) | Configuração aplicada em relógio | |
| BR302013005120S1 (pt) | Configuração aplicada em relógio | |
| BR302013005122S1 (pt) | Configuração aplicada em relógio | |
| BR302013005123S1 (pt) | Configuração aplicada em relógio | |
| BR302013005119S1 (pt) | Configuração aplicada em relógio | |
| BR302013005124S1 (pt) | Configuração aplicada em relógio |